Technical Analysis for FATE - Fate Therapeutics, Inc.
|Grade||Last Price||% Change||Price Change|
FATE closed down 2.97 percent on Thursday, June 21, 2018, on 83 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
|Weak or Absent||Up||Up||Up|
|See historical FATE trend table...|
|Date||Alert Name||Type||% Chg|
|Jun 21||Stochastic Reached Overbought||Strength||0.00%|
|Jun 21||Upper Bollinger Band Walk||Strength||0.00%|
|Jun 21||Above Upper BB||Strength||0.00%|
|Jun 21||Overbought Stochastic||Strength||0.00%|
|Jun 21||Upper Bollinger Band Touch||Strength||0.00%|
|Jun 20||BB Squeeze Ended||Range Expansion||-2.97%|
|Jun 20||Above Upper BB||Strength||-2.97%|
|Jun 20||Gapped Up||Strength||-2.97%|
|Jun 20||Upper Bollinger Band Touch||Strength||-2.97%|
|Jun 19||Bollinger Band Squeeze||Range Contraction||6.26%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops pharmacologic modulators of adult stem cells to treat orphan diseases. Its HSC modulation platform focuses on the ex vivo pharmacologic optimization of hematopoietic stem cells, which are adult stem cells that regenerate various types of blood cells throughout a person's lifespan; and SSC modulation platform focuses on the in vivo pharmacologic activation of satellite stem cells that are adult stem cells that regenerate muscle throughout a person's lifespan. The company's products include ProHema, a pharmacologically-modulated HSC therapeutic derived from umbilical cord blood that is in Phase II clinical trials for hematologic malignancies in adult patients. It also plans to conduct clinical trials of ProHema for hematopoietic reconstitution in hematologic malignancies and lysosomal storage disorders in pediatric patients. In addition, the company is developing Wnt7a Analogs that is in preclinical studies for regeneration in muscular dystrophies. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more FATE news...
|52 Week High||14.45|
|52 Week Low||2.52|
|200-Day Moving Average||7.8692|
|50-Day Moving Average||11.0858|
|20-Day Moving Average||11.653|
|10-Day Moving Average||12.074|
|Average True Range||0.8694|
|Chandelier Exit (Long, 3 ATRs )||11.2418|
|Chandelier Exit (Short, 3 ATRs )||12.6182|
|Upper Bollinger Band||12.9903|
|Lower Bollinger Band||10.3157|
|Percent B (%b)||1.03|
|MACD Signal Line||0.3362|
|Market Cap||541.7 Million|
|Num Shares||41.4 Million|
|Price-to-Earnings (P/E) Ratio||-13.63|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||14.83|
|Resistance 3 (R3)||14.89||14.37||14.54|
|Resistance 2 (R2)||14.37||13.92||14.34||14.44|
|Resistance 1 (R1)||13.73||13.65||13.47||13.66||14.34|
|Support 1 (S1)||12.56||12.76||12.30||12.50||11.82|
|Support 2 (S2)||12.04||12.49||12.01||11.72|
|Support 3 (S3)||11.40||12.04||11.62|
|Support 4 (S4)||11.33|